NCT01931748已完成3 期
Study of Non-inferiority UNCNT Versus MELSMON in Female With Menopausal Syndrome: Randomized Confirmatory Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 2
- 主要终点
- Kupperman index score
研究概览
简要总结
The Purpose of this study is to evaluate in a randomized, double-blind, Parallel, Non-inferiority, Multicenter, the efficacy and safety of UNCNT in comparison to the active comparator of MELSMON in female having menopausal syndrome. Patients will be allocated randomly to receive either UNCNT or MELSMON.
Through the injection of UNCNT to female having menopausal disorder, efficacy in the improvement of the menopausal symptoms by Kupperman index is to be evaluated and compared with MELSMON.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Woman ≥ 40 years old
- •Corresponding to one of the following criteria : Postmenopausal woman
- •spontaneous amenorrhea for 12 month
- •Blood serum of FSH concentration exceeds 40mlU/mL, spontaneous amenorrhea for 6month
- •passed for at least 6 weeks of bilateral ovariectomy
- •History of bilateral hysterectomy pasted at least 6week and blood serum of FSH more than 40mLU/ml
- •Confirmed using a hot flashes recorded daily diary at visit 2: More 3-4 (times/ per day) moderate or severe flush at least a day or occurrence of more than 20 times a week to check flush
- •Kupperman Index Score ≥ 15 point
- •Serum Estradiol ≤ 30pg/mL
- •Able to communicate to conduct the clinical trial according to the protocol
- •Informed consent by oneself
排除标准
- •Allergic to drugs or any ingredient
- •Psychological menopausal disorder
- •History of carcinoma such as liver cancer etc
- •In the investigator's judgment, which will be unable to participate in this study
- •uncontrolled hypertensive(170/110mmHg more), severe disease (eg., of the cardiovascular, liver, kidney) or diabetic mellitus
- •History of hysterectomy or bilateral ovariectomy within 6 weeks
- •Patients whose blood serum AST/ALT, bilirubin and creatinine are more two times the normal maximum rate.
- •Receiving hormone therapy such as estrogen, progestin or hormone of this class within a month
- •Patients are participated in other clinical trials, and then receiving investigational product within 3 months.
- •Usage of prohibit combination dug
- •history of alcohol and drug abuse
- •Washout requirement for hormone therapy such as estrogen or products involved like estrogen/progestin component ( If who has washout period of following criteria, the subject can participate in this study)
- •hormonal vaginal formulation (ring, cream, gels, etc) ≥ 1 weeks
- •estrogen single agent or estrogen/progestin-containing subcutaneous formulation ≥ 4 weeks
- •Oral estrogen or progestin therapy ≥ 8 weeks
- •Progestin intrauterine therapy ≥ 8 weeks
- •single injection of estrogen and progestin formulation transplant ≥3 month
- •injection of progestin or estrogen pellet method ≥ 6 month
- •In woman ≥40 age, known or suspicion of breast cancer at Breast angiographic and normal pregnancy breast test within 9 month; history of breast cancer; Family history of breast cancer in one generation
- •In Thickness of uterine intima ≥5mm as determined by TUVS, known or suspicion of endometrial hyperplasia or endometrial cancer by performing the endometrial biopsy
- •known or suspicion of Cervical cancer in pap test ( pap smear)
- •otoscleorsis
- •Taking rifampicin induced liver microsome enzyme ( eg., Barbiturates, Hydantion, carbamazepine, mepeu donkey mate, John diphenyl butadiene)
- •Jaundice, Dubin-Johnson syndrome or Rotor syndrome
- •Vaginal bleeding for unknown reason
- •Sickle cell anemia
- •Severe metabolic disorder (eg., porphyria..)
- •Thrombotic phlebitis, thrombosis, embolism patients, or those patients with a history
- •Cerebral, coronary altery disease
- •Thyroid disease, infectious disease
- •Experience of using placenta drug
- •Other circumstances that make the investigator expect an incomplete study participation of the patient
研究组 & 干预措施
UNCNT
Experimental
6 times/ 12 days
干预措施: UNCNT (Drug)
MELSMON
Active Comparator
6 times/ 12 days
干预措施: MELSMON (Drug)
结局指标
主要结局
Kupperman index score
时间窗: baseline and 12days
Mean difference of single clinical symptom in Kupperman index from baseline to 12days
次要结局
- E2(baseline and 12days)
- FSH (Folic Stimulating Hormone)(baseline and 12days)
- Hot flushes(baseline and 12days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Potential numbing affects of Urtica feroxPainNeurological - Other neurological disordersACTRN12619000804189elson Marlborough Institute of Technology9
已完成
2 期
operamide versus Racecadotril in management of Radiation EnteritisCTRI/2020/04/024721IMRF162
进行中（未招募）
1 期
Estudio de no inferioridad, en grupos paralelos, multicéntrico, aleatorizado y abierto de las inyecciones subcutáneas de RO0503821 administradas una vez al mes comparado con darbepoetin alfa administrado de acuerdo con la información declarada en la ficha técnica del producto en pacientes con nefropatía crónica que no están en diálisis. - STELLATAefropatía crónicaMedDRA version: 8.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaEUCTR2006-004552-21-ESF. Hoffmann-La Roche Ltd200
招募中
Unknown
Prospective randomized study on non-inferiority analysis/equivalence analysis of the surgical procedures GreenLight and Rezum for benign prostatic hyperplasia (AG BPH)N40Hyperplasia of prostateDRKS00034013Charite- Universitätsmedizin Berlin160
进行中（未招募）
1 期
Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day and Micronized Purified Flavonoid Fraction 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD).symptomatic Chronic Venous Disease (CVD).MedDRA version: 20.0 Level: LLT Classification code 10066682 Term: Chronic venous insufficiency System Organ Class: 100000004866EUCTR2017-003633-28-ATInstitut de Recherches Internationales SERVIER (I.R.I.S.)570